References

  • Kim YH, Lee SM, Cho S, Kang JH, Minn YK, Park H, Choi SH (2019) “Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease.” Sci Rep 9:4966 https://doi.org/10.1038/s41598-019-41429-1.
  • Weller RO, Galea I, Carare RO, Minagar A (2010). “Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis.” Pathophysiol.(4): 295-306.
  • Brand AL, Lawler PE, Bollinger JG et al. (2022) “The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review.” Alz Res Therapy 14:195. https://doi.org/10.1186/s13195-022-01117-1
  • Mander BA, Abhishek DA, Lui KK, Sprecher KE, Berisha D, Chappel-Farley MG, Chen IY, Riedner BA, Heston M, Suridjan I, Kollmorgen G, Zetterberg H, Blennow K, Carlsson CM, Okonkwo OC, Asthana S, Johnson SC, Bendlin BB, Benca RM, (2022) “Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to β-amyloid positivity, Sleep 45(9), zsac135, https://doi.org/10.1093/sleep/zsac135
  • Jessen NA, Munk AS, Lundgaard I, Nedergaard M. (2015) “The Glymphatic System: A Beginner’s Guide.” Neurochem Res. 40(12):2583-2599. doi: 10.1007/s11064-015-1581-6.
  • Dong TTT, Satoh K. (2021) “The Latest Research on RT-QuIC Assays,A Literature Review.” Pathogens. 10(3):305. https://doi.org/10.3390/pathogens10030305
  • Duan S, Yang J, Cui Z, Li J, Zheng H, Zhao T, Yuan Y, Liu Y, Zhao L, Wang Y, Luo H, Xu Y. (2023) “Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases.” Transl Neurodegener. 12(1):13. doi: 10.1186/s40035-023-00345-1.
  • Kovacs T, Cairns NJ, Lantos PL (1999) “b-Amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer’s disease.” Neuropathology and Applied Neurobiology 25:481-491.
  • Arnold SE, Lee EB, Moberg PJ, Stutzbach L, Kazi H, Han LY, Lee VMY, Trojanowski JQ (2010) “Olfactory epithelium amyloid-β and paired helical filament-tau pathology in Alzheimer disease.” Ann Neurol., 67:462-469. https://doi.org/10.1002/ana.21910.
  • Tsai H, Phinney BS, Grigorean G, Salemi MR, Hooman H. Rashidi HH, Pepper J, Tran NK (2022) “Identification of Endogenous Peptides in Nasal Swab Transport Media used in MALDI-TOF-MS Based COVID-19 Screening ” ACS Omega 7(20):17462-17471 doi:10.1021/acsomega.2c01864.
  • Condello C, Westaway D, Prusiner SB. (2024) “Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases.” JAMA Neurol. Published online August 19, 2024. doi:10.1001/jamaneurol.2024.2464
  • [Kim, Y.H., Lee, SM., Cho, S. et al. Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease. Sci Rep 9, 4966 (2019). https://doi.org/10.1038/s41598-019-41429-1
  • Kameshima N, Yanagisawa D, Tooyama I (2013) “ß-Amyloid peptide (1–40) in the brain reaches the nasal cavity via a non-blood pathway. Neurosci. Res. 76, 169–172.
  • Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. (2018) “NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers.” Dement. 14:535–562.
  • Malou N, Raoult D (2011) “Immuno-PCR: a promising ultrasensitive diagnostic method to detect antigens and antibodies.” Trends in microbiology, 19(6):295-302.
  • Geng D et al. (2022) “Sleep EEG-Based Approach to Detect Mild Cognitive Impairment.” Frontiers in Aging Neuroscience,. 14:865558.
  • Jung DH, et al., (2022) “Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer’s Disease.” Pharmaceutics 14(8):1532.
  • Rossini PM, Miraglia F, Vecchio F, (2022) “Early dementia diagnosis, MCI‐to‐dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis.” Alzheimer’s & Dementia 18(12):2699-2706.
  • Kopčanová M et al., (2024) “Resting-state EEG signatures of Alzheimer’s disease are driven by periodic but not aperiodic changes.” Neurobiology of Disease 190:106380.
  • Silva RCD, de Lima SC, Dos Santos Reis WPM, de Magalhães JJF, Magalhães RNO, Rathi B, Kohl A, Bezerra MAC, Pena L, (2023) “Comparison of DNA extraction methods for COVID-19 host genetics studies.” PLoS One.18(10):e0287551. doi: 10.1371/journal.pone.0287551.
  • Zhong L, Xie YZ, Cao TT, Wang Z, Wang T, Li X, Shen RC, Xu H, Bu G, Chen XF. (2016) “A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism.” Mol. Neurodegener.11:2. doi: 10.1186/s13024-016-0069-4.
  • Zhou S, Tu L, Chen W, Yan G, Guo H, Wang X, Hu Q, Liu H, Li F. (2023) “Alzheimer’s disease, a metabolic disorder: Clinical advances and basic model studies.” Exp Ther Med.27(2):63. doi: 10.3892/etm.2023.12351.
  • Honea RA, John CS, Green ZD, Kueck PJ, Taylor MK, Lepping RJ, Townley R, Vidoni ED, Burns JM, Morris JK. (2022) “Relationship of fasting glucose and longitudinal Alzheimer’s disease imaging markers.” Alzheimers Dement (NY) 8(1):e12239. doi: 10.1002/trc2.12239.
  • Lei R, Mohan C. (2020) “Immunological Biomarkers of COVID-19.” Crit Rev Immunol.40(6):497-512. doi: 10.1615/CritRevImmunol.2020035652
  • Noyola DE, Clark B, O’Donnell FT, Atmar RL, Greer J, Demmler GJ, (2000) “Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens.” J Clin Microbiol.38(3):1161-5. doi: 10.1128/JCM.38.3.1161-1165.2000.
  • Yoo S.J, Son G, Bae J, Kim SY, Yoo YK, Park D, Baek SY, Chang KA, Suh YH, Lee YB, Hwang KS, Kim Y, Moon C, (2020) “Longitudinal profiling of oligomeric Aβ in human nasal discharge reflecting cognitive decline in probable Alzheimer’s disease.” Scientific Reports, 2020. 10(1):11234.
  • Slinger R, Milk R, Gaboury I, Diaz-Mitoma F. (2004) “Evaluation of the QuickLab RSV test, a new rapid lateral-flow immunoassay for detection of respiratory syncytial virus antigen.” J Clin Microbiol. 42(8):3731-3. doi: 10.1128/JCM.42.8.3731-3733.2004.
  • Swanson CJ, Zhang Y, Dhadda, S. et al. (2021) “A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody.” Alz Res Therapy 13:80. https://doi.org/10.1186/s13195-021-00813-8.
  • Kim MJ, Haizan I, Ahn MJ, Park D-H, Choi J-H. (2024) “Recent Advances in Lateral Flow Assays for Viral Protein Detection with Nanomaterial-Based Optical Sensors.” Biosensors 14(4):197. https://doi.org/10.3390/bios14040197.
  • Kim HT, Jin E, Lee MH. (2021) “Portable Chemiluminescence-Based Lateral Flow Assay Platform for the Detection of Cortisol in Human Serum.” Biosensors (Basel) 11(6):191. doi: 10.3390/bios11060191.
  • Tian X, Zhao Y, Zhu Y, Cui M (2024) “Association between elevated blood-brain barrier permeability and the risk of progressive cognitive decline: A longitudinal study” Archives of Gerontology and Geriatrics 124: 105441, https://doi.org/10.1016/j.archger.2024.105441.
  • Hathaway E, Morgan K, Carson M, Shusterman R, Fernandez-Corazza M, Luu P, Tucker, DM, (2021) “Transcranial Electrical Stimulation targeting limbic cortex increases the duration of human deep sleep.” Sleep medicine, 81: 350-357.
  • Iliff JJ, Elbert DL, Giovangrandi L, Singh T, Venkatesh VV, Corbellini A, Kaplan RA, Ludington E, Yarasheski K, Lowenkron J, VandeWeerd C, Lim MM, Dagum, P. (2024) “The glymphatic system clears amyloid beta and tau from brain to plasma in humans.” medRxiv 2024.07.30.24311248; doi: https://doi.org/10.1101/2024.07.30.24311248
  • Morgan K. Doncov A, Lim MM, Elliott JE, Tinsley CE, Levendovzsky SR, Tucker DM. (2024). “Transcranial Electrical Synchronization of Slow Oscillations to Enhance Deep Sleep at Home for Healthy Adults.” Presented at the Military Health Research Symposium, Orlando, FL. https://mhsrs.health.mil/
  • Xie L, Kang H, Xu,Q, Chen MJ, Liao,Y, Thiyagarajan M, O’Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R,1 Nedergaard, M. (2013) “Sleep drives metabolite clearance from the adult brain.” Science, 342(6156): a373-377.
  • Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. (2024) “Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.” JAMA. Published online July 28, 2024. doi:10.1001/jama.2024.13855.
  • Giudici KV, de Souto Barreto P, Guyonnet S, Li Y, Bateman RJ, Vellas B; MAPT/DSA (2020) “Group. Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults.” JAMA Netw Open.3(12):e2028634. doi: 10.1001/jamanetworkopen.2020.28634.
  • Hanon O, Vidal JS, Lehmann S, et al. (2018) “Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers.” Alzheimers Dement. 14(7): 858–868.
  • Gonzalez-Ortiz, F., Kac, P.R., Brum, W.S. et al. (2023) “Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications.” Mol Neurodegeneration 18:18. https://doi.org/10.1186/s13024-023-00605-8
  • Hampel H,Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O’Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Schindler SE, (2023) “Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape.” Neuron 111(18):2781-2799.
  • Perneczky R, Jessen F, Grimmer T, et al. (2023) “Anti-amyloid antibody therapies in Alzheimer’s disease.” Brain 46(3):842-849. doi:10.1093/ brain/awad005
  • Liu Z et al. (2018) “Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau” Journal of Alzheimer’s Disease 62(2): 737-744.
  • Lan Z, Yiyuan X, Yuran G (2023) “Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets.” Frontiers in Aging Neuroscience 15-2023, DOI=10.3389/fnagi.2023.1199434
  • Perra D, Bongianni M, Novi G, Janes F, et al. (2021) “Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies, Brain Comm.3(2):fcab045 https://doi.org/10.1093/braincomms/fcab045.
  • Wang J, Huang S, Lan G, Lai YJ, Wang QH, Chen Y, Xiao ZS, Chen X, Bu XL, Liu YH, Zeng F, Zhang L, Li A, Cai Y, Sun P, He Z, Doré V, Fripp J, Bourgeat P, Chen Q, Yu JT, Tang Y, Zetterberg H, Masters CL, Guo T, Wang YJ; “Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN). Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer’s disease in clinical and community cohorts.” Alzheimers Dement. 2025 Mar;21(3):e70038. doi: 10.1002/alz.70038.
  • Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C, Bateman RJ, Holtzman DM, Irizarry M, Verbel D, Sachdev P, Ito S, Contois J, Yarasheski KE, Braunstein JB, Verghese PB, West T. “Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.” Alzheimers Dement. 2024 May;20(5):3179-3192. doi: 10.1002/alz.13764.
  • Schöll M, Verberk IMW, Del Campo M, Delaby C, Therriault J, Chong JR, Palmqvist S, Alcolea D. (2024) “Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease.” Lancet Healthy Longevity 5(10):100630. doi: 10.1016/j.lanhl.2024.07.013.
  • Ashton NJ, Zetterberg H. (2025) “A blood test for Alzheimer’s disease: a decade of progress and success.” EBioMedicine 112:105545. doi: 10.1016/j.ebiom.2024.105545.
  • King S, Trabanino S, Azizi Z, Rodriguez F. (2024) “Leveraging Social Determinants of Health to Enhance Recruitment of Underrepresented Populations in Clinical Trials.” Methodist Debakey Cardiovasc J. (5):81-88. doi: 10.14797/mdcvj.1447.